Sugi Predict

Sugi Predict / Targets / ACP3

ACP3

Prostatic acid phosphatase · P15309 · ACP3 on Sugi Atlas →

20,500 patent compounds predicted against ACP3, 10,655 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL232244 SCHEMBL232244 0.79 16/20
SCHEMBL232549 SCHEMBL232549 0.53 13/20
SCHEMBL777888 SCHEMBL777888 0.64 12/20
SCHEMBL777805 SCHEMBL777805 0.57 11/20
SCHEMBL170512 SCHEMBL170512 0.53 11/20
SCHEMBL776864 SCHEMBL776864 0.58 10/20
SCHEMBL776850 SCHEMBL776850 0.51 10/20
SCHEMBL778799 SCHEMBL778799 0.56 9/20
SCHEMBL777580 SCHEMBL777580 0.53 8/20
SCHEMBL445039 SCHEMBL445039 0.56 7/20
SCHEMBL613995 SCHEMBL613995 0.44 7/20
SCHEMBL716635 SCHEMBL716635 0.39 7/20
SCHEMBL777639 SCHEMBL777639 0.62 5/20
SCHEMBL777991 SCHEMBL777991 0.53 5/20
Amino(Phenyl)Methylphosphonic Acid Amino(Phenyl)Methylphosphonic Acid (SCHEMBL233491) 0.50 5/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL607712) 0.59 4/20
SCHEMBL382130 SCHEMBL382130 0.53 4/20
SCHEMBL407877 SCHEMBL407877 0.50 4/20
SCHEMBL237456 SCHEMBL237456 0.49 4/20
SCHEMBL777249 SCHEMBL777249 0.49 4/20

Clinical trials — most relevant to ACP3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer PHASE3COMPLETED
Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer PHASE2ACTIVE_NOT_RECRUITING
Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer PHASE2WITHDRAWN
A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer PHASE2COMPLETED
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression PHASE2RECRUITING
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer PHASE2ACTIVE_NOT_RECRUITING
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial PHASE2RECRUITING
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss PHASE2RECRUITING
A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate Cancer PHASE1RECRUITING
A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer PHASE1COMPLETED
18F-DCFBC PET/CT in Prostate Cancer EARLY_PHASE1COMPLETED
Theranostic Applications of Radionuclides in Prostate Cancer nanRECRUITING
Predictive Nomogram of CRPC nanUNKNOWN
Prostate Cancer Antigen 3 (PCA-3) Gene Project nanCOMPLETED
Biomarkers of Bone Resorption in Metastatic Prostate Cancer nanCOMPLETED
A Prospective, Single-centre，Single-blinded Study of PROUD for Prostate Carcinoma Diagnosis nanUNKNOWN
Clinical Evaluation of the PROGENSA(Registered Trademark) Prostate Cancer Gene 3 (PCA3) Assay in Men With a Previous Negative Biopsy Result nanCOMPLETED
Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer nanUNKNOWN
A Pilot Study to Assess the Immunogenicity of Candidate PSA Peptides for a Prostate Cancer Vaccine nanCOMPLETED
PRO-STATE:Search for a Protein Profile Corresponding to Fast-developing Lesions and Characterization of Implicated Proteins in Prostate Carcinoma nanCOMPLETED
Chemokine Mechanisms in Chronic Pelvic Pain nanCOMPLETED
Predicting Prostate Biopsy Results With Biomarkers and mpMRI. nanCOMPLETED
Study of Robotic Template Guidance for Needle Placement in Transperineal Prostate Brachytherapy nanCOMPLETED
Prostate Conformal Cryotherapy nanCOMPLETED
Does Protein Restriction Inhibit Prostrate Cancer Growth nanCOMPLETED
Proteases in Patients With Prostate Cancer That Has Spread to the Bone nanCOMPLETED
Prognostic Study of Via Dynamic Change of PCA3 mRNA in Drainage Fluid After Radical Prostatectomy nanNOT_YET_RECRUITING
Cancer DNA Detection in Blood and Urine nanCOMPLETED
Planetary Habitat Simulation: Bone Metabolism Studies nanCOMPLETED
Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ACP3 binder may also engage these)

ProteinNameSimilarity
Q8CE08 — 1.000 Q8CE08 →
A6H730 — 1.000 A6H730 →
P20646 — 1.000 P20646 →
Q0P5F0 — 0.977 Q0P5F0 →
P24638 — 0.975 P24638 →
Q5NVF6 — 0.973 Q5NVF6 →
P20611 — 0.973 P20611 →
P11117 — 0.973 P11117 →
B1H1P9 — 0.967 B1H1P9 →
Q4R5N9 — 0.967 Q4R5N9 →
Q3KQG9 — 0.964 Q3KQG9 →
D2GZV9 — 0.949 D2GZV9 →
Q9WUZ9 — 0.948 Q9WUZ9 →
A6H757 — 0.948 A6H757 →
Q6P6S9 — 0.948 Q6P6S9 →
Q9NPH0 — 0.946 Q9NPH0 →
Q14CH1 — 0.946 Q14CH1 →
Q5R8C0 — 0.946 Q5R8C0 →
E1BPW0 — 0.944 E1BPW0 →
ENTPD5 Nucleoside diphosphate phosphatase ENTPD5 0.943 landscape →
E1C1L6 — 0.943 E1C1L6 →
P58242 — 0.943 P58242 →
ENPP1 Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 0.943 landscape →
P49614 — 0.943 P49614 →
P24822 — 0.942 P24822 →
Q29548 — 0.941 Q29548 →
P08430 — 0.941 P08430 →
Q3U0P5 — 0.940 Q3U0P5 →
B6EWW8 — 0.940 B6EWW8 →
Q6AXR4 — 0.940 Q6AXR4 →